Concord Drugs Ltd Share Price (538965)
as on
| Source : BSE
Concord Drugs Ltd Stock Performance
as on August 18, 2025 at 4:01 PM IST
- ₹51₹51
52 Week's Low
52 Week's High
₹26.1₹67
48.82%
Downside
31.37%
Upside
| Market Stats | |
| Previous Close | ₹52.04 |
| Open | ₹51.00 |
| Volume | 817.00 |
| Upper Circuit | ₹53.08 |
| Lower Circuit | ₹51.00 |
| Day's Low | ₹51 |
| Day's High | ₹51 |
| 52 Week Low | ₹26.1 |
| 52 Week High | ₹67 |
| Returns % | |
| 1 Month Return | -14.42 % |
| 3 Month Return | + 61.46 % |
| 1 Year Return | + 59.83 % |
| 3 Year Return | + 89.24 % |
| 5 Year Return | + 241.69 % |
Concord Drugs Ltd Stock Fundamentals & Key Indicators
Check Concord Drugs Ltd market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹52.04 Cr
Return on Equity (ROE)
1.28
PE Ratio (TTM)
121.02
Return on capital employed (ROCE)
4.25
Industry PE ratio
43.28
Beta (LTM)
0.59
P/B Ratio
1.04
Dividend Yield
0PEG Ratio
318.48
Quarterly Earnings Growth YOY
300
EPS (TTM)
0.47
Sector
Pharmaceuticals
Book Value
33.82
Technical Analysis
Bullish
View Technical Analysis
Concord Drugs Ltd Stock's Interest Amongst Investors
Concord Drugs Ltd Stock Valuation
Track how Concord Drugs Ltd P/E has moved over time to understand its valuation trends.
Concord Drugs Ltd in the last 5 years
Lowest (-961.50x)
January 3, 2025
Industry (43.28x)
August 14, 2025
Today (121.02x)
August 14, 2025
Highest (791.40x)
July 3, 2024
Today’s Price to Earnings Ratio: 121.02x
Concord Drugs Ltd Financial Results
Get the annual and quarterly financial summary of Concord Drugs Ltd, including revenue, profit, loss and more.
Concord Drugs Ltd Earnings and Dividends
View detailed summary of the earnings and dividend history of Concord Drugs Ltd.
Concord Drugs Ltd Earnings Results
Concord Drugs Ltd’s net profit jumped 300% since last year same period to ₹0.12Cr in the Q1 2025-2026. On a quarterly growth basis, Concord Drugs Ltd has generated 200% jump in its net profits since last 3-months.
Read More about Earnings Results
Concord Drugs Ltd Stock Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Concord Drugs Ltd.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 54.39% | 0.00 | |
| Foreign Institutions | 0% | 0.00 | |
| Mutual Funds | 0% | 0.00 | |
| Retail Investors | 45.61% | 0.00 | |
| Others | 0% | 0.00 |
Concord Drugs Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Concord Drugs Ltd with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| NA | 52.04 | 48.34% | 0.69 | 1 | 44 | |
| NA | 697.24 | -1.55% | 0.00 | 30 | 245 | |
| NA | 21.07 | 16.64% | 0.00 | NA | 14 | |
| NA | 2,189.31 | 31.46% | 0.53 | 60 | 759 | |
| NA | 7,764.41 | 8.94% | 0.51 | 305 | 1,942 |
Insights on Concord Drugs Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 2 quarters, 0.04 Cr → 0.12 Cr (in ₹), with an average increase of 66.7% per quarter
- POSITIVE IMPACT
Price Rise
In the last 3 months, Concord Drugs stock has moved up by 61.5%
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, Concord Drugs has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 10.4 Cr → 13.61 Cr (in ₹), with an average increase of 23.6% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 54.39% of holdings in Jun 2025 quarter
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 132.1% return, outperforming this stock by 42.9%
- NO EFFECT
Retail Holding Unchanged
Retail Investor holdings remained unchanged at 45.61% of holdings in Jun 2025 quarter
About Concord Drugs Ltd
Revenue: ₹13.61Cr as on June 2025 (Q1 FY26)
Net Profit: ₹0.12Cr as on June 2025 (Q1 FY26)
Chairperson Name: S Nagi Reddy
| Organisation | Concord Drugs Ltd |
| Industry | Pharmaceuticals |
| CEO | S Nagi Reddy |
| E-voting on shares | Click here to vote |
FAQs
What is Concord Drugs Ltd share price today?
Concord Drugs Ltd share price today stands at ₹51, Open: ₹51, Previous Close: ₹52.04, High: ₹51, Low: ₹51, 52 Week High: ₹67, 52 Week Low: ₹26.1 as on .
How to buy Concord Drugs Ltd shares ?
To buy Concord Drugs Ltd shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for 538965 or Concord Drugs Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Concord Drugs Ltd shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is today's traded volume of Concord Drugs Ltd?
Today's traded volume of Concord Drugs Ltd is 817.00. Which means that 817.00 shares of Concord Drugs Ltd were bought and sold on the stock market during today's trading session.
What is Concord Drugs Ltd's market cap today?
Today's market capitalisation of Concord Drugs Ltd is ₹52.04 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Concord Drugs Ltd?
Concord Drugs Ltd’s 52 week high is ₹67 and 52 week low is ₹26.1. The current share price of Concord Drugs Ltd is ₹51, which is -23.88% down from its 52 week high and 95.40% up from its 52 week low.